Schistosomiasis vaccine development: progress and prospects

Nr, Bergquist

doi:10.1590/s0074-02761998000700013

Cited by 52 publications

(36 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is endemic in 74 countries causing more than 250,000 deaths per year [1]. Despite two decades of comprehensive campaign for the control, the number of individuals with active schistosomiasis worldwide remains at about 200 million annually [2,3].…”

Section: Introductionmentioning

confidence: 99%

Proteome approach for identification of schistosomiasis japonica vaccine candidate antigen

Abdel-Hafeez

Kikuchi

Watanabe

et al. 2009

Parasitology International

View full text Add to dashboard Cite

Experimental vaccination with radiation-attenuated cercariae (RAC) confers possible practical levels of resistance to challenge infection by humoral and by cellular mechanism. Here, we aimed to identify possible vaccine antigens by using specific IgG antibody from RAC vaccinated miniature pig. Two milligrams of soluble egg antigen (SEA) or schistosomal worm antigen preparation (SWAP) was fractionated using two dimensional liquid chromatography From the positive fractions we chose 17 of SEA and 10 of SWAP that had no reactivity with normal cercariae infected (NCI) sera and had single peak of 214 nm; and automated N-terminal amino acid sequence based on in situ Edman Reaction was conducted. Four sequences were obtained and applied to the homology search in NCBI database. A total of eight candidate genes were listed up and their cDNA clones from schistosomula stage were obtained. Two of the recombinant proteins (AAW27472.1 and AXX25883.1) showed strong reactivity with the RAC vaccinated serum but marginal with NCI serum. This protocol using proteome PF2D could be applicable in identifying immunoreactive proteins from crude extract for the development of vaccines or for diagnostics.

show abstract

Section: Introductionmentioning

confidence: 99%

Proteome approach for identification of schistosomiasis japonica vaccine candidate antigen

Abdel-Hafeez

Kikuchi

Watanabe

et al. 2009

Parasitology International

View full text Add to dashboard Cite

show abstract

“…In most cases the disease can be successfully treated by chemotherapy, but rapid reinfection rates for patients in endemic areas require repeated treatment, sometimes as often as once a year. Thus, there is a need for complementary long-term control measures, such as a vaccine (5,6). Protection levels as high as 90% have been reported for the use of irradiated cercaria for immunization of a variety of animal models, ranging from rodents to nonhuman primates (11,27).…”

mentioning

confidence: 99%

“…Extensive research on the biology of the parasite has identified six candidate antigens, which are currently included in a World Health Organization-sponsored program to develop a vaccine for the improved control of schistosomiasis (5,6).…”

mentioning

confidence: 99%

RecombinantMycobacterium bovisBCG Expressing the Sm14 Antigen ofSchistosoma mansoniProtects Mice from Cercarial Challenge

et al. 2004

View full text Add to dashboard Cite

The Sm14 antigen of Schistosoma mansoni was cloned and expressed in Mycobacterium bovis BCG as a fusion with the Mycobacterium fortuitum ␤-lactamase protein under the control of its promoter, pBlaF*; the protein was localized in the bacterial cell wall. The rBCG-Sm14 strain was shown to be relatively stable in cultured murine and bovine monocytes in terms of infectivity, bacterial persistence, and plasmid stability. The immunization of mice with rBCG-Sm14 showed no induction of anti-Sm14 antibodies; however, splenocytes of immunized mice released increased levels of gamma interferon upon stimulation with recombinant Sm14 (rSm14), indicating an induction of a Th1-predominant cellular response against Sm14. Mice immunized with one or two doses of rBCG-Sm14 and challenged with live S. mansoni cercaria showed a 48% reduction in worm burden, which was comparable to that obtained by immunization with three doses of rSm14 purified from Escherichia coli. The data presented here further enhance the status of Sm14 as a promising candidate antigen for the control of schistosomiasis and indicate that a one-dose regimen of rBCG-Sm14 could be considered a convenient means to overcome many of the practical problems associated with the successful implementation of a multiple-dose vaccine schedule in developing countries.

show abstract

“…Currently, schistosomiasis control strategy is mainly based on the treatment of infected individuals by chemotherapy with safe and effective drugs (Harder 2002). In spite of two decades of chemotherapy, the number of infected people remains almost the same (Bergquist 1998). Therefore, vaccination as a way to control schistosomiasis would contribute enormously to disease eradication, mainly because immunization provides long-lasting immunity to the disease.…”

mentioning

confidence: 99%

Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells

Fonseca

Cunha‐Neto

Kalil

et al. 2004

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Schistosomiasis vaccine development: progress and prospects

Cited by 52 publications

References 29 publications

Proteome approach for identification of schistosomiasis japonica vaccine candidate antigen

Proteome approach for identification of schistosomiasis japonica vaccine candidate antigen

RecombinantMycobacterium bovisBCG Expressing the Sm14 Antigen ofSchistosoma mansoniProtects Mice from Cercarial Challenge

Identification of immunodominant epitopes of Schistosoma mansoni vaccine candidate antigens using human T cells

Contact Info

Product

Resources

About